Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting

Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting
Arcturus Therapeutics unveils OTC research

Arcturus Therapeutics is set to present its latest research on ornithine transcarbamylase (OTC) deficiency at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company is inviting attendees to visit Poster 52 to learn more about developments in its OTC deficiency program.

OTC deficiency is a rare genetic disorder that disrupts the urea cycle, posing serious health challenges. Arcturus Therapeutics's work in mRNA-based therapies targets these inherited metabolic diseases and represents an ongoing commitment to advancing the field. Further details of the program and research will be available at the conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.